

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,
INNOPHARMA INC., INNOPHARMA LLC, MYLAN PHARMACEUTICALS
INC., and MYLAN INC.
Petitioner,

v.

SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and
BAUSCH & LOMB PHARMA HOLDINGS CORP.
Patent Owner.

Case IPR2015-00903
Patent 8,129,431

**PATENT OWNER RESPONSE
PURSUANT TO 37 C.F.R. § 42.120**

Table of Contents

I.	Introduction	2
II.	Statement of relief requested	6
III.	Claim construction	6
IV.	Level of ordinary skill in the art	6
V.	The '431 patent	7
VI.	Background of ophthalmic formulations	7
VII.	The combination of Ogawa and Sallmann, in either direction, does not render any claim of the '431 patent obvious	8
A.	No reason to focus on Ogawa and bromfenac preparations	8
B.	Design need and market demands would not have led a POSA in the direction that the inventors of the '431 patent took	9
C.	A POSA would not have combined Ogawa and Sallmann	14
	1. Ogawa and the problem it sought to solve	14
	2. Sallmann's singular purpose does not align with Ogawa's	16
	3. It would not have been obvious to modify Ogawa Example 6 in view of Sallmann Example 2	18
	4. InnoPharma's arguments of motivation and expectation of success ring hollow	25
D.	Sallmann in view of Ogawa: another hindsight-laden combination	28
	1. The proposed combination destroys the essential purpose of Sallmann and ignores the blaze marks in the art	28

2.	InnoPharma's arguments to modify Sallmann in view of Ogawa are legally insufficient, internally inconsistent, and belied by the very art InnoPharma cites	31
E.	Fu does not remedy the deficiencies of Ogawa and Sallmann	35
1.	A POSA would not have looked to Fu	35
2.	InnoPharma's attempted connection between Fu and tyloxapol is untenable	36
3.	InnoPharma has failed to prove unpatentability of claims 6, 15-17 and 20-22, requiring about 0.02 w/v % tyloxapol	40
VIII.	Compelling objective evidence of patentability	45
A.	Tyloxapol's unexpectedly superior chemical stabilizing effect	46
1.	Testing against the closest prior art	46
2.	A POSA's expectation, if anything, of polysorbate 80	47
3.	Tyloxapol's unexpectedly superior stabilizing effect	48
4.	Tyloxapol's unexpectedly better maintenance of preservative efficacy	54
B.	Additional compelling objective evidence of patentability	55
IX.	Conclusion	60

Table of Authorities

	Page(s)
Cases	
<i>Allergan v. Sandoz</i> , 796 F.3d 1293 (Fed. Cir. 2015)	<i>passim</i>
<i>In re Antonie</i> , 559 F.2d 618 (C.C.P.A. 1977)	41, 42, 45
<i>Atlas Powder Co. v. E.I. du Pont De Nemours & Co.</i> , 750 F.2d 1569 (Fed. Cir. 1984)	31
<i>Cadence Pharm. Inc. v. Exela PharmSci Inc.</i> , 780 F.3d 1364 (Fed. Cir. 2015)	<i>passim</i>
<i>Catalina Lighting, Inc. v. Lamps Plus, Inc.</i> , 295 F.3d 1277 (Fed. Cir. 2002)	45
<i>Depuy Spine, Inc. v. Medtronic Sofamor Danek, Inc.</i> , 567 F.3d 1314 (Fed. Cir. 2009)	10, 12, 27, 31
<i>Eisai Co. Ltd. v. Dr. Reddy's Labs., Ltd.</i> , 533 F.3d 1353 (Fed. Cir. 2008)	19, 23, 24
<i>In re Gordon</i> , 733 F.2d 900 (Fed. Cir. 1984)	28
<i>In re Gurley</i> , 27 F.3d 551 (Fed. Cir. 1994)	13, 23
<i>In re Huai-Hung Kao</i> , 639 F.3d 1057 (Fed. Cir. 2011)	53
<i>Insite Vision Inc., v. Sandoz, Inc.</i> , 783 F.3d 853 (Fed. Cir. 2015)	13, 30, 37
<i>Institut Pasteur v. Focarino</i> , 738 F.3d 1337 (Fed. Cir. 2013)	60

<i>Janssen Pharm. NV v. Mylan Pharm., Inc.</i> , 456 F. Supp. 2d 644 (D.N.J. 2006), <i>aff'd per curiam</i> , 223 Fed. Appx. 999 (Fed. Cir. 2007).....	59
<i>KSR Int'l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007).....	32
<i>Microsoft Corp. v. Proxycorr, Inc.</i> , 789 F. 3d 1292 (Fed. Cir. 2015)	6
<i>Ortho-McNeil Pharm. Inc. v. Mylan Labs, Inc.</i> , 520 F.3d 1358(Fed. Cir. 2008)	45
<i>In re Papesch</i> , 315 F.2d 381 (C.C.P.A. 1963).....	42, 53
<i>Pfizer Inc. v. Mylan Pharm. Inc.</i> , 2014 WL 5388100 (D. Del. 2014).....	21, 30, 36, 37
<i>In re Siebentritt</i> , 372 F.2d 566 (C.C.P.A. 1967)	18, 19
<i>Specialty Composites v. Cabot Corp.</i> , 845 F.2d 981 (Fed. Cir. 1988)	59
<i>Syntex LLC v. Apotex Inc.</i> , 2006 U.S. Dist. Lexis 36089 (N.D. Cal. 2006), <i>aff'd</i> 221 Fed. Appx. 1002 (Fed. Cir. 2007).....	23, 25, 39
<i>Unigene Labs. v. Apotex, Inc.</i> , 655 F.3d 1352 (Fed. Cir. 2011)	19
<i>In re Wesslau</i> , 353 F.2d 238 (C.C.P.A. 1965)	22, 29
Statutes	
35 U.S.C. §119	7
35 U.S.C. § 316(e)	1

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.